denosumab-desu

FDA Drug Profile — JUBEREQ, OSVYRTI

denosumab-desu is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand names including JUBEREQ, OSVYRTI. Available dosage form: injection.

Drug details

Generic Name
denosumab-desu
Brand Names
JUBEREQ, OSVYRTI
Application Number
BLA761424
Sponsor
Accord BioPharma Inc.
NDC Codes
2
Dosage Forms
INJECTION
Routes
SUBCUTANEOUS
Active Ingredients
DENOSUMAB

Indications and Usage

1 INDICATIONS AND USAGE Jubereq is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 ) 1.1 Multiple Myeloma and Bone Metastasis from Solid Tumors Jubereq is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. 1.2 Giant Cell Tumor of Bone Jubereq is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity [see Clinical Trials ( 14.2 )] . 1.3 Hypercalcemia of Malignancy Jubereq is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.